MARKET

RAPP

RAPP

Rapport Therapeutics Inc
NASDAQ
25.96
-0.11
-0.42%
After Hours: 25.96 0 0.00% 19:30 11/10 EST
OPEN
25.83
PREV CLOSE
26.07
HIGH
26.90
LOW
25.30
VOLUME
660.15K
TURNOVER
--
52 WEEK HIGH
52.93
52 WEEK LOW
22.06
MARKET CAP
1.54B
P/E (TTM)
-8.1826
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RAPP last week (1102-1106)?
Weekly Report · 1d ago
Rapport Therapeutics Is Maintained at Buy by UBS
Dow Jones · 5d ago
Rapport Therapeutics Price Target Cut to $64.00/Share From $71.00 by UBS
Dow Jones · 5d ago
UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64
Benzinga · 5d ago
Rapport Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 5d ago
Rapport Therapeutics Price Target Cut to $66.00/Share From $70.00 by Guggenheim
Dow Jones · 5d ago
Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66
Benzinga · 5d ago
Rapport Therapeutics Is Maintained at Overweight by Wells Fargo
Dow Jones · 5d ago
More
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.

Webull offers Rapport Therapeutics Inc stock information, including NASDAQ: RAPP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPP stock methods without spending real money on the virtual paper trading platform.